Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03485911 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
A Phase 3 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 121
- Enrollment target
NCT03485911 is a Phase 3 study that has completed, run by BioCryst Pharmaceuticals. The registered enrollment target is 121 participants.
The verdict
NCT03485911, a Phase 3 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 121 participants
- Enrollment target
Study Summary
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.
Interventions
- DRUG Placebo oral capsule
- DRUG BCX7353 capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2018-02-06 |
| Est. Completion | 2022-04-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03485911
The ClinicalTrials.gov registry entry for NCT03485911 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03485911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03485911 about?
NCT03485911 is a clinical study titled "Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE". This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.
What is the current status of trial NCT03485911?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 121 participants. The study started on 2018-02-06. Estimated completion is 2022-04-06.
What interventions are being tested in trial NCT03485911?
The interventions under investigation include: Placebo oral capsule (DRUG), BCX7353 capsules (DRUG).
Who is sponsoring clinical trial NCT03485911?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.